Viking Therapeutics stock falling amid results for new GLP-1 pill
Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and competition between pharmaceutical rivals in the GLP-1 weight-loss drug space. Viking reported positive results for its new obesity pill,
Viking Therapeutics Inc (VKTX) Stock: More Resilient Than It Appears
On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $64.63 which represents a slight increase of $1.49 or 2.36% from the prior close of $63.14. The stock opened at $63.
Viking Therapeutics Stock Climbs On Positive Data From VK2735 Obesity Program
Shares of Viking Therapeutics, Inc. (VKTX) were gaining around 17 percent in the pre-market activity on the Nasdaq after the company
Viking Therapeutics soars then drops on obesity data
Jared Holz, Mizuho, joins 'Fast Money' to talk Viking Therapeutics and the biotech sector. NFL News: 49ers confirm the final update on Christian McCaffrey's return Yellowstone coyote not alone; can you spot the other mammal?
Viking stock fluctuates amid manufacturing concerns with obesity pill
Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.
Viking stock drops 13% after jumping 9% on obesity drug data
Shares of Viking Therapeutics (NASDAQ:VKTX) fell 13% Monday afternoon after jumping 9% earlier in the day amid concerns that the company might face production problems for its promising weight-loss drug candidate VK2735.
Viking Tops Novo As Obesity Pill Brawl Continues, But Shares Dive
Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo Nordisk — after just four weeks of treatment. But, after rallying in premarket trades and opening higher,
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
Viking Therapeutics (VKTX) Gets a Buy from Truist Financial
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
Should you buy Viking Therapeutics (VKTX) after today’s spike?
Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.
Viking shares jump after positive early data on oral obesity pill; Lilly, Novo drop
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...
bovnews4d
A Pill for the Future: Viking Therapeutics (VKTX) Takes Center Stage in Obesity Solutions
As Viking Therapeutics continues to advance its clinical programs, the implications for patients and investors are substantial. The promising early results from VK2735 not only signify a potential ...
SchaeffersResearch.com4d
Biotech Stock Reverses Gains Despite Obesity Pill Buzz
Viking Therapeutics (VKTX) stock is reversing gains despite earlier announcing strong results for its experimental obesity pill ...
Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
Viking Therapeutics VKTX has outperformed the market over the past 5 years by 49.88% on an annualized basis producing an ...
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Viking Therapeutics Inc (NASDAQ:VKTX) announced that new clinical data from the company’s VK2735 obesity program were ...
Morningstar4d
Viking Therapeutics Inc VKTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Viking Therapeutics participates in a conference call with JPMorgan
Conference call with CEO Dr. Lian and CFO Zante to be held on November 5 at 11:30 am hosted by JPMorgan. Webcast Link Published first on ...